Category: Hill-Rom Holdings Inc.
Hill-Rom's next generation airway clearing system lands a nod from the FDA
Hill-Rom Holdings (NYSE:HRC) landed 510(k) clearance from the FDA for its MetaNeb 4.0 airway clearing system, which combines airway oscillation and pressure to expand weak lungs and encourage normal mucus growth.
NxStage names Robert Funari its new chairman, following the resignation of Philippe Chambon after 15 years on the medical device company's board.
NxStage Medical (NSDQ:NXTM) named Robert Funari to replace Philippe Chambon as non-executive chairman after 15 years on the medical device company's board of directors.
Medical devices made a lot of headlines in 2012, and the word "layoffs" was in many of them.
The medical device industry had a lot of big stories during the last year, including tales of recalls, lawsuits and CEO swapping, but the single factor that drove more big headlines than any other was news of layoffs.
Some of the biggest companies in the industry announced significant cuts in 2012, amounting to about 7,000 reported layoffs, by some estimates.
Hill-Rom and Stryker settle a patent infringement lawsuit over powered hospital bed wheels.
Shares of Hill-Rom Holdings gain 6% after the medical device company beats Wall Street's expectations with its 4th-quarter and fiscal 2012 results.
Hill-Rom Holdings (NYSE:HRC) added 6% to its share price this week after reporting 4th-quarter and fiscal 2012 profits ahead of analysts' expectations.
Batesville, Ind.-based Hill-Rom posted Q4 profits of $39.2 million, or 63¢ per share, on sales of $330.1 million for the 3 months ended Sept. 30. That represents a sales increase of 4.4%, but a bottom-line decrease of 38.3%.
Shares of NuVasive are down more than 30% today after the medical device company lowered its outlook for the rest of the year.
NuVasive Inc. (NSDQ:NUVA) shares are down more than 30% today after the medical device company said yesterday that its 3rd-quarter results are likely to be substantially lower than predicted.
San Diego-based NuVasive, which makes spinal surgery implants, said 3rd-quarter sales will be about $147 million, 4.8% below the roughly $154.4 million the company expected to post.
